Latest Us Market News

LTR Pharma has secured a binding US telehealth commercialisation framework for its intranasal erectile dysfunction treatment ROXUS, committing to at least 150,000 prescriptions in the first year and granting exclusivity to Shed Holdings' platform.

ArborGen Holdings announces CEO Justin Birch's resignation after three years, appointing Patrick Cumbie as interim CEO while searching for a permanent replacement.

GCM Corporation is seeking shareholder approval for a 15-to-1 share consolidation as a strategic step towards a potential listing on a US national stock exchange, aiming to boost international capital access and market visibility.

First Graphene accelerates its US expansion by acquiring MITO Material Solutions, gaining functionalised graphene technologies and a direct commercial foothold in the world’s largest defence and aerospace market.

Control Bionics advances its neural-signal technology across assistive communication, sports, and medical sectors, securing key US reimbursement and distribution agreements while broadening its international footprint.

Pacific Edge has secured NZ$36.1 million through a combination of a NZ$25.4 million placement and a significantly oversubscribed retail offer, reinforcing its strategic position to expand the Cxbladder cancer diagnostic platform.

DroneShield has landed a $24.9 million contract with the US Department of War’s Joint Interagency Task Force 401 to supply mobile and fixed counter-drone solutions, reinforcing its foothold in the US defence market.

Pure Resources has appointed retired US Navy Vice Admiral Jeff Trussler to its advisory board, aiming to fast-track US government funding and integration of its advanced materials into defence supply chains.

QuickFee Limited has reported a robust 77% increase in Australian originations for Q4 FY26 to-date, driven by strong Fee Funding and Disbursement Funding growth. The company boosted its Australian credit facility by A$15 million, signalling confidence in its low-risk lending model, while US operations focus on reseller channel expansion amid a product embedding delay.

Nova Minerals shareholders and Nasdaq warrantholders overwhelmingly approved schemes to restructure the company under a new US holding entity, pending final court approval.

PolyNovo has completed its pivotal US clinical trial report for NovoSorb BTM and adjusted its FDA Premarket Approval submission timeline to late 2026 to incorporate updated regulatory requirements and additional data.

ArborGen Holdings delivered its strongest revenue in five years with $68.2 million, driven by a 14% surge in Brazil and an 8% rise in adjusted EBITDA despite US market headwinds. The company’s focus on advanced genetics and operational efficiency underpins a confident FY27 outlook.